J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit People visit the booth of Johnson & Johnson at the China International Import Expo (CIIE) in Shanghai, China November 7, 2024. REUTERS/Andrew Silver · Reuters By Michael Erman Wed, July 15, 2026 at 12:27 PM GMT+2 2 min read JNJ By Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya ‌and cancer blockbuster Darzalex more than offset erosion from older products and ‌a drop in sales for heart pumps it picked up in its 2022 acquisition of Abiomed. J&J also increased ​its full-year sales and profit forecast.

The healthcare conglomerate reported second-quarter sales of $25. 31 billion, up 6. 6% from a year earlier and above analysts' average estimate of about $25.

05 billion, according to LSEG data. Adjusted earnings were $2. 90 per share, up 4.

7% from a year ago and topping analyst expectations ‌of $2. 85. It now expects sales of ⁠about $101.

1 billion at the midpoint, from $100. 8 billion previously. The company also raised its adjusted earnings per share forecast to $11.

68 at the midpoint, ⁠from $11. 55 previously. The company said its pharmaceutical unit generated $16.

38 billion in quarterly sales, ahead of analyst estimates of $16. 1 billion. Sales of its psoriasis and inflammatory bowel disease drug Tremfya rose 72.

5% to $2 billion, ​compared with ​LSEG estimates of $1. 74 billion. Tremfya has become increasingly ​important as J&J works to replace ‌sales lost from Stelara, whose revenue has fallen sharply after losing its patent protection.

Second-quarter sales of blood cancer treatment Darzalex were $4. 2 billion in the quarter, roughly in line with analyst estimates. Sales at J&J's medical technology unit were $8.

93 billion, slightly trailing analyst estimates. CFO Joseph Wolk said in an interview that Abiomed sales in the quarter were hurt after publication ‌of a U. K.

study that raised questions about ​the use of Impella pumps during certain high-risk coronary ​procedures. Abiomed sales in the quarter ​fell 2% year over year, compared with 14% growth in the ‌first quarter. He said J&J expects the franchise ​to return to growth, ​particularly as the company releases more data showing the utility of the pumps.

"We have a big data set coming out probably in the first half of ​next year that should allay ‌any fears," Wolk said. "When you have 28 platforms that generate at least $1 ​billion in revenue on an annual basis, we're not dependent on one asset.